These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 2287298)
21. Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America. Sader HS; Carvalhaes CG; Streit JM; Castanheira M; Flamm RK Int J Infect Dis; 2020 Feb; 91():32-37. PubMed ID: 31715325 [TBL] [Abstract][Full Text] [Related]
22. [Assessment of the susceptibility of the gram-negative rods isolated from hospitalized patients to cefoperazone/sulbactam]. Młynarczyk G; Młynarczyk A; Wysocka PC; Scibisz A; Kostyra K; Sańczyk E; Jezewska G; Sliwa R; Winek K; Wolska M; Pastuszak A; Serafin I; Łuczak M Med Dosw Mikrobiol; 2008; 60(1):51-8. PubMed ID: 18634344 [TBL] [Abstract][Full Text] [Related]
23. In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone. Chandrasekar PH; Sluchak JA Infection; 1991; 19(1):49-53. PubMed ID: 2013510 [TBL] [Abstract][Full Text] [Related]
24. [In vitro activities of aztreonam and sulbactam/ampicillin for gram-negative bacteria]. Ozkuyumcu C; Durupinar B; Dikmen N Mikrobiyol Bul; 1989 Jan; 23(1):77-9. PubMed ID: 2626099 [TBL] [Abstract][Full Text] [Related]
25. In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria. Lim VK; Halijah MY Med J Malaysia; 2001 Sep; 56(3):365-9. PubMed ID: 11732084 [TBL] [Abstract][Full Text] [Related]
26. [Three-year experience with the use of cefoperazone/sulbactam (sulperazone) in the treatment of hospital-acquired infections in an oncologic hospital]. Antibiot Khimioter; 2006; 51(1):14-7. PubMed ID: 16734360 [TBL] [Abstract][Full Text] [Related]
27. The susceptibility of non-fermentative Gram-negative bacilli to cefperazone and sulbactam compared with other antibacterial agents. Fu W; Demei Z; Shi W; Fupin H; Yingyuan Z Int J Antimicrob Agents; 2003 Oct; 22(4):444-8. PubMed ID: 14522108 [TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro and in vivo activity of cefminox (MT-141), cefotaxime and cefoperazone against gram-negative bacteria. Watanabe T; Kazuno Y; Hirano F; Inouye S; Nishino T Drugs Exp Clin Res; 1985; 11(11):781-6. PubMed ID: 3841789 [TBL] [Abstract][Full Text] [Related]
31. Multicentre study on antibiotic susceptibilities of anaerobic bacteria to cefoperazone-sulbactam and other antimicrobial agents. Clark RB; Bartelt MA; Chan EL; Dalton HP J Antimicrob Chemother; 1992 Jan; 29(1):57-67. PubMed ID: 1737725 [TBL] [Abstract][Full Text] [Related]
32. Molecular correlation between in vitro and in vivo activity of beta-lactam and beta-lactamase inhibitor combinations against methicillin-resistant Staphylococcus aureus. Fasola EL; Fasching CE; Peterson LR J Lab Clin Med; 1995 Feb; 125(2):200-11. PubMed ID: 7844469 [TBL] [Abstract][Full Text] [Related]
33. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp]. Vay CA; Almuzara MN; Rodríguez CH; Pugliese ML; Lorenzo Barba F; Mattera JC; Famiglietti AM Rev Argent Microbiol; 2005; 37(1):34-45. PubMed ID: 15991478 [TBL] [Abstract][Full Text] [Related]
34. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination. Jones RN; Barry AL; Packer RR; Gregory WW; Thornsberry C J Clin Microbiol; 1987 Sep; 25(9):1725-9. PubMed ID: 3498740 [TBL] [Abstract][Full Text] [Related]
35. Ceftriaxone against gram-negative and gram-positive bacteria: bactericidal and post-antibiotic effect. Ravizzola G; Bonfanti C; Savoldi E; Turano A Chemioterapia; 1985 Jun; 4(3):204-8. PubMed ID: 3875430 [TBL] [Abstract][Full Text] [Related]
36. In vitro activity of the combination trimethoprim plus sulfamethoxazole compared with that of other chemotherapeutic agents. Focht J; Klietmann W; Nösner K Arzneimittelforschung; 1988 Aug; 38(8):1085-8. PubMed ID: 3264166 [TBL] [Abstract][Full Text] [Related]
37. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin. Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G Drugs Exp Clin Res; 1987; 13(9):555-61. PubMed ID: 3480796 [TBL] [Abstract][Full Text] [Related]
38. Current status of drug resistance among gram-negative bacilli isolated from admitted cases in a tertiary care centre. Chitnis SV; Chitnis V; Sharma N; Chitnis DS J Assoc Physicians India; 2003 Jan; 51():28-32. PubMed ID: 12693450 [TBL] [Abstract][Full Text] [Related]
39. In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data. Hung MN; Hsueh PR; Chang HT; Lee WS; Chou MY; Chen IS; Wang JH; Lin CF; Shyr JM; Ko WC; Wu JJ; Liu YC; Huang WK; Teng LJ; Liu CY; Luh KT Int J Antimicrob Agents; 2007 Feb; 29(2):145-52. PubMed ID: 16815690 [TBL] [Abstract][Full Text] [Related]
40. [Comparison of the in vitro effectiveness of sulbactam/ampicillin and ampicillin]. Baykal M; Akalin E Mikrobiyol Bul; 1987 Jan; 21(1):16-9. PubMed ID: 3441224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]